Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

  • Díez-Alonso, Laura
  • Falgàs, Aïda
  • Arroyo-Ródenas, Javier
  • Romencín, Paola A
  • Martínez, Alba
  • Gómez-Rosel, Marina
  • Blanco, Belén
  • Jiménez-Reinoso, Anaïs
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Ramírez-Fernández, Ángel
  • Segura-Tudela, Alejandro
  • Perez-Amill, Lorena
  • Tapia-Galisteo, Antonio
  • Domínguez-Alonso, Carmen
  • Rubio-Pérez, Laura
  • Jara-Acevedo, Maria
  • Solé, Francesc
  • Hangiu, Oana
  • Almagro, Laura
  • Albitre, Ángela
  • Penela, Petronila
  • Sanz, Laura
  • Anguita, Eduardo
  • Valeri, Antonio
  • García-Ortiz, Almudena
  • Río, Paula
  • Juan, Manel
  • Martínez-López, Joaquín
  • Roda-Navarro, Pedro
  • Martin-Antonio, Beatriz
  • Orfao, Alberto
  • Menéndez, Pablo
  • Bueno, Clara
  • Álvarez-Vallina, Luis
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric antigen receptors (CARs) and systemically injected bispecific T cell engagers (TCEs), has shown remarkable clinical activity, and several products have received market approval. However, despite promising results, most patients eventually become refractory and relapse, highlighting the need for alternative strategies. Engineered T cells secreting TCE antibodies (STAb) represent a promising strategy that combines the advantages of adoptive cell therapies and bispecific antibodies. Here, we undertook a comprehensive preclinical study comparing the therapeutic potential of T cells either expressing second-generation anti-BCMA CARs (CAR-T) or secreting BCMAxCD3 TCEs (STAb-T) in a T cell–limiting experimental setting mimicking the conditions found in patients with relapsed/refractory multiple myeloma. STAb-T cells recruited T cell activity at extremely low effector-to-target ratios and were resistant to inhibition mediated by soluble BCMA released from the cell surface, resulting in enhanced cytotoxic responses and prevention of immune escape of multiple myeloma cells in vitro. These advantages led to robust expansion and persistence of STAb-T cells in vivo, generating long-lived memory BCMA-specific responses that could control multiple myeloma progression in xenograft models, outperforming traditional CAR-T cells. These promising preclinical results encourage clinical testing of the BCMA-STAb-T cell approach in relapsed/refractory multiple myeloma., Financial support for this work was obtained from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00 to P.R.-N., PID2019-108160RB-I00 to P.M., PLE2021-0075 to C.B., and PID2020-117323RB-100 and PDC2021-121711-100 to L.Á.-V.), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (PI20/01030 to B.B., PI19/00132 to L.S., PI21-01834 to P.P., PI20/00822 to C.B., and DTS20/00089 to L.Á.-V.), partially supported by the ERDF; the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia) (RD21/0017/0030 to B.B. and J.M.-L. and RD21/0017/0029 to P.M.); the ISCIII-CIBERONC program (CB16/12/00400 to A.O.), the CRIS Cancer Foundation (FCRIS-2021-001 to J.M.-L. and FCRIS-2021-0090 to L.Á.-V.), the Spanish Association Against Cancer (AECC) (PRYGN234975MENE to P.M., PRYGN211192BUEN to C.B., and PROYE19084ALVA and PRYGN234844ALVA to L.Á.-V.); the Accelerator Award-Cancer Research UK/AIRC/AECC-INCAR (GEACC18001ORF to A.O.), the Fundación “La Caixa” (LCF/PR/HR19/52160011 to P.M. and HR21-00761 project IL7R_LungCan to L.Á.-V.), the European Research Council (ERC) (ERC-PoC-957466 to P.M.) and ERC under the EU’s Horizon Program (grant agreement 101100665 to P.M.), the Fundación de Investigación Biomédica 12 de Octubre (programa Investiga 2022-0082) to L.Á.-V.; the Fundación Ramón Areces to P.P. L.D.-A. was supported by a Rio Hortega fellowship from the Carlos III Health Institute (CM20/00004). A.F. was supported by a postdoctoral fellowship from the Spanish Ministry of Science and Innovation (FJC2021-046789-I). A. Mayado was supported by the CIBERONC (PRF-2869). A.P.-P. was supported by a grant from the Government of Castilla y León (Orden EDU/556/2019; Valladolid, Spain). M.G.-R. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD-23732). O.A.-S. was supported by a PhD fellowship from the Complutense University of Madrid. C.D.-A. was supported by a PhD fellowship from the Spanish Ministry of Science and Innovation (PRE2018-083445). L.R.-P. was supported by a PhD fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. O.H. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2020/BMD-17668). A.V. is supported by Research Institute Hospital 12 de Octubre (imas12). A.G.-O. is supported by HIGEA 2019/0123 AIE project to J.M.-L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutierrez-Agüera, Francisco
  • Zanetti, Samanta Romina
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu, Sergi
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela
  • Guedan, Sonia
  • Sanz, Laura
  • Toribio, María L.
  • Roda-Navarro, Pedro
  • Juan, Manel
  • Menéndez, Pablo
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies., European Research Council (CoG-2014-646903, PoC-2018-811220) Spanish Ministry of Science and Innovation (PID2019-105623RB-I00, SAF2016-75656-P, RTC-2017-5944-1, SAF-2019-108160-R, SAF2017-89437-P, PID2020-117323RB-100, PDC2021-121711-100) Carlos III Health Institute (PI20/01030, PI20/00822, PI16/00357, PI19/00132, PICI14/122, PI13/676, PIE13/33, PI18/775, DTS20/00089) CatSalut, Fundació La Caixa (CP042702) Spanish Association Against Cancer (AECC CICPF18030TORI, AECC 19084) CRIS Cancer Foundation (FCRIS-IFI-2018, FCRIS-IFI-2020) Spanish Ministry of Science and Innovation under a Ramon y Cajal grant (RYC2018-024442-I) Comunidad Autónoma de Madrid (PEJD-2018- PRE/BMD-8314) ISCIII (CM20/00004) Spanish Ministry of Science and Innovation (PRE2018-083445) Portuguese Foundation for Science and Technology (SFRH/BD/136574/2018)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Benchmark Side-by-Side Comparison of Two Well-Established Protocols for in vitro Hematopoietic Differentiation From Human Pluripotent Stem Cells

  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Rodriguez-Cortez, Virginia Carolina
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
The generation of transplantable hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) remains challenging. Current differentiation protocols from hPSCs generate mostly hematopoietic progenitors of the primitive HSC-independent program, and it remains unclear what is the best combination of cytokines and hematopoietic growth factors (HGFs) for obtaining functional hematopoietic cells in vitro. Here, we have used the AND1 and H9 hESC lines and the H9:dual-reporter RUNX1C-GFP-SOX17-Cherry to compare the hematopoietic differentiation in vitro based on the treatment of embryoid bodies (EBs) with the ventral mesoderm inducer BMP4 plus HGFs in the absence (protocol 1) or presence (protocol 2) of stage-specific activation of Wnt/β-catenin and inhibition of Activin/Nodal. Despite a slight trend in favor of protocol 1, no statistically significant differences were observed between protocols at any time point analyzed throughout EB development regarding the frequency of hemogenic endothelial (HE) precursors; CD43+ CD45-, CD45+, and CD45 + CD34 + hematopoietic derivatives; or the output of clonogenic progenitors. Similarly, the kinetics of emergence throughout EB development of both SOX17 + HE and RUNX1C + definitive hematopoiesis was very similar for both protocols. The expression of the early master mesendodermal transcription factors Brachyury, MIXL1, and KDR revealed similar gene expression kinetics prior to the emergence of RUNX1C + definitive hematopoiesis for both protocols. Collectively, the simpler protocol 1 is, at least, as efficient as protocol 2, suggesting that supplementation with additional morphogens/HGFs and modulation of Activin/Nodal and Wnt/β-catenin pathways seem dispensable for in vitro hematopoietic differentiation of hPSCs
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Blanco, Joan|||0000-0003-0647-3856
  • Bueno, Clara|||0000-0003-1442-6216
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Bataller, Alex|||0000-0002-6085-2745
  • López-Millán, Belén|||0000-0002-9757-5454
  • Schwab, Claire
  • Ortega, Margarita
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Blanco, María L.
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Fuster, José Luis|||0000-0002-4881-9440
  • Cuatrecasas, Esther|||0000-0003-2881-4412
  • Camós, Mireia|||0000-0003-3658-7942
  • Ballerini, Paola
  • Escherich, Gabriele
  • Boer, Judith
  • DenBoer, Monique
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Harrison, Christine J.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Molina, Oscar|||0000-0001-7585-4519
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells

  • Rodriguez-Cortez, Virginia C.
  • Navarrete-Meneses, Maria Pilar
  • Molina, Oscar|||0000-0001-7585-4519
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • González, Jéssica
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Kowarz, Eric
  • Marin, Pedro
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gomez-Marin, Carlos
  • Perez-Vera, Patricia
  • Cortes-Ledesma, Felipe
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Terron, Andrea
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia

  • López-Millán, Belén|||0000-0002-9757-5454
  • Costales, Paula
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Rubio Gayarre, Alba
  • Safi, Rémi|||0000-0002-1697-872X
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Rodríguez-Manzaneque, Juan Carlos|||0000-0001-5951-7029
  • Bueno, Clara|||0000-0003-1442-6216
  • Morís, Francisco
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Patients with AML harboring a constitutively active internal tandem duplication mutation (ITD) in the FMS-like kinase tyrosine kinase (FLT3) receptor generally have a poor prognosis. Several tyrosine kinase/FLT3 inhibitors have been developed and tested clinically, but very few (midostaurin and gilteritinib) have thus far been FDA/EMA-approved for patients with newly diagnosed or relapse/refractory FLT3-ITD AML. Disappointingly, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITD AML. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin with a potent and selective inhibitory effect on FLT3. In vitro, EC-70124 exerted a robust and specific antileukemia activity against FLT3-ITD AML primary cells and cell lines with respect to cytotoxicity, CFU capacity, apoptosis and cell cycle while sparing healthy hematopoietic (stem/progenitor) cells. We also analyzed its efficacy in vivo as monotherapy using two different xenograft models: an aggressive and systemic model based on MOLM-13 cells and a patient-derived xenograft model. Orally disposable EC-70124 exerted a potent inhibitory effect on the growth of FLT3-ITD AML cells, delaying disease progression and debulking the leukemia. Collectively, our findings show that EC-70124 is a promising and safe agent for the treatment of AML with FLT3-ITD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CD34 + CD19 - CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

  • Bueno, Clara|||0000-0003-1442-6216
  • Barrera, Susana
  • Bataller, Alex|||0000-0002-6085-2745
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Elliot, Natalina
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Wang, Guanlin
  • Rovira, Montse
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • González-González, María|||0000-0001-8115-1086
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sorigue, Marc|||0000-0002-0587-591X
  • Bárcena, Paloma
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Torrebadell, Montse|||0000-0002-0027-3215
  • Vega-Garcia, Nerea
  • Rives, Susana|||0000-0002-5658-1831
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Sole, F.|||0000-0002-3251-2161
  • Mead, Adam J.|||0000-0001-8522-1002
  • Roberts, Irene|||0000-0002-6094-6397
  • Thongjuea, Supat|||0000-0002-9129-4694
  • Psaila, Bethan|||0000-0001-8198-9663
  • Juan, Manel|||0000-0002-3064-1648
  • Delgado, Julio|||0000-0002-5157-4376
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Orfao, Alberto|||0000-0002-0007-7230
  • Roy, Anindita
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. Maciocia and colleagues identify CCR9 as an antigen expressed on.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara|||0000-0003-1442-6216
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Guedan, Sonia|||0000-0002-9605-0760
  • Sanz, Laura
  • Toribio, Maria L.
  • Roda-Navarro, Pedro
  • Juan, Manel|||0000-0002-3064-1648
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

  • Molina, Oscar|||0000-0001-7585-4519
  • Ortega-Sabater, C.
  • Thampi, Namitha|||0000-0001-6166-583X
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Bueno, Clara|||0000-0003-1442-6216
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Granada, Isabel|||0000-0002-4275-0104
  • Campos, Diana
  • Giménez, Carles
  • Boer, Judith M.|||0000-0003-4848-7789
  • den Boer, Monique L.
  • Calvo, Gabriel F.|||0000-0002-3623-236X
  • Camós, Mireia|||0000-0003-3658-7942
  • Fuster, José Luis|||0000-0002-4881-9440
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Mullighan, Charles G.|||0000-0002-1871-1850
  • Spierings, Diana C.J.|||0000-0001-8403-474X
  • Foijer, Floris|||0000-0003-0989-3127
  • Pérez-García, Víctor M.|||0000-0002-6575-495X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

  • Marin-Bejar, Oskar
  • Romero Moya, Damià|||0000-0001-9947-3577
  • Rodriguez-Ubreva, Javier
  • Distefano, Maximiliano
  • Lessi, Francesca
  • Aretini, Paolo|||0000-0003-1075-4319
  • Liquori, Alessandro|||0000-0002-4842-5986
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Kozyra, Emilia|||0000-0003-1107-8818
  • Kotmayer, Lili|||0000-0002-5089-7659
  • Bueno, Clara|||0000-0003-1442-6216
  • Cervera, José|||0000-0001-8252-1106
  • Rodriguez-Gallego, José Carlos
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Murillo- Sanjuán, Laura
  • de Heredia, Cristina Díaz
  • Pérez-Martinez, Antonio
  • López-Cadenas, Félix
  • Martínez-Laperche, Carolina
  • Dorado-Herrero, Nieves
  • Marco, Francisco M.
  • Prósper, Felipe
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Valcárcel, David|||0000-0002-8747-078X
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Bödör, Csaba|||0000-0002-0729-692X
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Català, Albert|||0000-0003-0133-1752
  • Wlodarski, Marcin W.|||0000-0001-6638-9643
  • Giorgetti, Alessandra|||0000-0001-5803-3567
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

  • Bueno, Clara|||0000-0003-1442-6216
  • Martínez, Alba
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tirtakusuma, Ricky
  • Genesca, Eulalia
  • Camós, Mireia|||0000-0003-3658-7942
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Fuster, José Luis|||0000-0002-4881-9440
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low input capture Hi-C (liCHi-C) identifies promoter-enhancer interactions at high-resolution

  • Tomás Daza, Laureano|||0000-0002-6127-1694
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • López-Martí, Paula
  • Nieto-Aliseda, Andrea|||0000-0002-3238-8711
  • Serra, François|||0000-0003-3895-4742
  • Planas-Riverola, Ainhoa
  • Molina, Oscar|||0000-0001-7585-4519
  • McDonald, Rebecca|||0000-0002-6131-1748
  • Ghevaert, Cedric
  • Cuatrecasas, Esther|||0000-0003-2881-4412
  • Costa, Dolors|||0000-0002-8276-3292
  • Camós, Mireia|||0000-0003-3658-7942
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Valencia, Alonso
  • Javierre, B. M.|||0000-0002-8682-6748
Long-range interactions between regulatory elements and promoters are key in gene transcriptional control; however, their study requires large amounts of starting material, which is not compatible with clinical scenarios nor the study of rare cell populations. Here we introduce low input capture Hi-C (liCHi-C) as a cost-effective, flexible method to map and robustly compare promoter interactomes at high resolution. As proof of its broad applicability, we implement liCHi-C to study normal and malignant human hematopoietic hierarchy in clinical samples. We demonstrate that the dynamic promoter architecture identifies developmental trajectories and orchestrates transcriptional transitions during cell-state commitment. Moreover, liCHi-C enables the identification of disease-relevant cell types, genes and pathways potentially deregulated by non-coding alterations at distal regulatory elements. Finally, we show that liCHi-C can be harnessed to uncover genome-wide structural variants, resolve their breakpoints and infer their pathogenic effects. Collectively, our optimized liCHi-C method expands the study of 3D chromatin organization to unique, low-abundance cell populations, and offers an opportunity to uncover factors and regulatory networks involved in disease pathogenesis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Closa, Adria|||0000-0002-9302-337X
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Ximeno-Parpal, Pau|||0000-0003-1814-9607
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Beneyto Calabuig, Sergi|||0000-0003-3773-8239
  • Velten, Lars
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Casquero, Raquel
  • Abollo-Jiménez, Fernando
  • de la Guardia, Rafael D.
  • Lorden, Patricia
  • Bataller, Alex|||0000-0002-6085-2745
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Stam, Ronald W.
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Torrebadell, Montserrat
  • Fuster, José Luis|||0000-0002-4881-9440
  • Bueno, Clara|||0000-0003-1442-6216
  • Sarry, Jean Emmanuel
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Heyn, Holger|||0000-0002-3276-1889
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF and HIF specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.